NCT05342506 is a Phase 2 clinical trial of Toripalimab + ScTIL in Cervical Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05342506?

NCT05342506 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05342506?

Interventions in NCT05342506: Toripalimab + ScTIL.

What condition does NCT05342506 study?

NCT05342506 studies Cervical Cancer, Ovarian Cancer, Malignant Trophoblastic Tumor.

Is NCT05342506 still recruiting?

NCT05342506 is currently status unknown. Last updated 22 April 2022.

Last reviewed 2022-04-22 · How we verify

NCT05342506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Status unknown Phase 2 Last updated 22 April 2022

What this trial tests

Phase 2 trial testing Toripalimab + ScTIL in Cervical Cancer in 30 participants. Status unknown.

Timeline

18 April 2022

Primary endpoint
28 February 2024

31 May 2024

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	18 April 2022
Primary completion	28 February 2024
Estimated completion	31 May 2024

Drugs / interventions tested

Toripalimab + ScTIL — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →
Malignant Trophoblastic Tumor — all drugs for Malignant Trophoblastic Tumor →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, female only, with Cervical Cancer or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and clinical efficacy of ScTIL in the treatment of recurrent or refractory cervical cancer, ovarian cancer and malignant trophoblastic tumor, to evaluate the pharmacokinetic characteristics of ScTIL, and to explore and analyze the changes of CTC, ctDNA and immunohistochemical Library of malignant tumor subjects before and after ScTIL treatment.Treatment will be terminated upon progressive disease, unacceptable toxicity, or withdrawal of consent. Subjects with responses other than progressive disease will receive subsequent rounds of ScTIL treatment.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

T cells in health and disease.
Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM, Chan JJ. · · 2024 · cited 14× · PMID 38282261 · DOI 10.3802/jgo.2024.35.e65
Targeting immune microenvironment in cervical cancer: current research and advances.
Zhang Z, Liu M, An Y, Gao C, et al · · 2025 · cited 6× · PMID 40781691 · DOI 10.1186/s12967-025-06896-3
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.
Zhang W, Liu YM, Li D, Liu S, et al · · 2025 · cited 4× · PMID 40458394 · DOI 10.3389/fimmu.2025.1524842

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05342506 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 22 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05342506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing